While CAR-T cell therapy is showing promise in treating patients with advanced renal cell carcinoma, there is still more research that needs to be done in this arena.
Circulating tumor DNA which is observed via blood test may be helpful in determining which patients with kidney cancer need more intense treatment and who can have their therapies deescalated.
Decisions regarding the intensification or de-escalation of treatment, particularly with immunotherapy and TKIs, for patients with renal cell carcinoma could be aided by circulating tumor DNA.
Although not immediately practice changing, CAR T-cell therapy has the potential to become a standard of care for patients with advanced renal cell carcinoma following progression on checkpoint inhibitors and VEGF inhibitors.